Rethink of hepatectomy for hepatocellular carcinoma in the era of targeted immunotherapy
10.3877/cma.j.issn.2095-3232.2024.01.003
- Author:
Zhanguo Zhang
- Publication Type:Lectures
- From:
Chinese Journal of Hepatic Surgery（Electronic Edition）
2024;13(1):11-15
- CountryChina
- Language:Chinese
-
Abstract:
Surgery has been considered as the most effective treatment for hepatocellular carcinoma (HCC). In spite of almost 100-year development, the survival benefits brought by surgery for HCC patients have not been further improved. In recent years, widespread application of targeted drugs and immune checkpoint inhibitors have provided a novel development direction for comprehensive treatment and related research of HCC. With widespread clinical application, the advantages of targeted immune therapy in the treatment of HCC at all stages are constantly presented, which make surgeons rethink whether the original concept of surgery for HCC is still correct. In this article, the problems and potential solutions in hepatectomy for HCC in the era of targeted immunotherapy were in-depth discussed.
- Full text:202412021648450118611.pdf
